OTA’s CEO The OTA has a committee structure that gives on a range of diverse and sensitive issues. We key stakeholders the opportunity to participate acknowledge the contribution of the members in the decision-making processes that support and thank them for supporting the OTA in the implementation of the national reform raising public awareness of organ and tissue program. donation and implementing best practice organ The committee structure comprises: and tissue donation and transplantation processes » committees focusing on program governance throughout and advice, comprising the: Australia. Australian Organ and Tissue Donation — and Transplantation Advisory Council JURISDICTIONAL ADVISORY GROUP (from 1 July 2016 to 31 December The peak governance committee for the 2016) DonateLife Network (DLN) in 2016–17 was the Jurisdictional Advisory Group — Jurisdictional Advisory Group (JAG). It comprises State Medical Directors and jurisdictional health » committees established by the CEO to department representatives. provide sector-specific advice, comprising the: This group, chaired by the OTA’s CEO, Clinical Governance Committee considered and made recommendations about — all aspects of Transplant Liaison Reference Group — the national reform program. This includes » purpose-specific working groups. strategic priorities, clinical and data governance, and program planning for the DLN. A brief report on outcomes was published on the ADVISORY COUNCIL DonateLife website after each JAG meeting. The Australian Organ and Tissue Donation and From 1 July 2017 the JAG will provide Transplantation Advisory Council (the Advisory advice and recommendations to the OTA Council) was established under the Australian Board for consideration. Organ and Tissue Donation and Transplantation Authority Act 2008 (the Act) to advise the CEO on organ CLINICAL GOVERNANCE COMMITTEE and tissue donation and transplantation matters. The Advisory Council’s term ended in The Clinical Governance Committee is the peak December clinical committee for the DLN. It is chaired by 2016. The legislation that was passed in the National Medical Director and comprises the November CEO, State Medical Directors, and clinical 2016 established a new governance model for managers the OTA from 1 July 2017 and ended the term from each and territory. The committee of the Advisory Council. makes recommendations relating to the clinical aspects of the national reform program for During the period of the Advisory Council’s consideration by tenure, its members skilfully counselled the the JAG.
The OTA has a committee structure that gives key stakeholders the opportunity to participate in the decision-making processes that support the implementation of the national reform program. The committee structure comprises: » committees focusing on program governance and advice, comprising the: — Australian Organ and Tissue Donation and Transplantation Advisory Council (from 1 July 2016 to 31 December 2016) — Jurisdictional Advisory Group » committees established by the CEO to provide sector-specific advice, comprising the: — Clinical Governance Committee — Transplant Liaison Reference Group » purpose-specific working groups. ADVISORY COUNCIL The Australian Organ and Tissue Donation and Transplantation Advisory Council (the Advisory Council) was established under the Australian Organ and Tissue Donation and Transplantation Authority Act 2008 (the Act) to advise the CEO on organ and tissue donation and transplantation matters. The Advisory Council’s term ended in December 2016. The legislation that was passed in November 2016 established a new governance model for the OTA from 1 July 2017 and ended the term of the Advisory Council. During the period of the Advisory Council’s tenure, its members skilfully counselled the OTA’s CEO on a range of diverse and sensitive issues. We acknowledge the contribution of the members and thank them for supporting the OTA in raising public awareness of organ and tissue donation and implementing best practice organ and tissue donation and transplantation processes throughout Australia. JURISDICTIONAL ADVISORY GROUP The peak governance committee for the DonateLife Network (DLN) in 2016–17 was the Jurisdictional Advisory Group (JAG). It comprises State Medical Directors and jurisdictional health department representatives. This group, chaired by the OTA’s CEO, considered and made recommendations about all aspects of the national reform program. This includes strategic priorities, clinical and data governance, and program planning for the DLN. A brief report on outcomes was published on the DonateLife website after each JAG meeting. From 1 July 2017 the JAG will provide advice and recommendations to the OTA Board for consideration. CLINICAL GOVERNANCE COMMITTEE The Clinical Governance Committee is the peak clinical committee for the DLN. It is chaired by the National Medical Director and comprises the CEO, State Medical Directors, and clinical managers from each and territory. The committee makes recommendations relating to the clinical aspects of the national reform program for consideration by the JAG.
OTA%202016-17%20Annual%20Report%20(Parts%201-2).docx